What Lyell Immunopharma, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 9 | 29 |
| Total trades | 9 | 39 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 1,012,930 |
| Disposed | 14,188 | 256,275 |
| Net activity | −14,188 | +756,655 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Aguirre Jarrad Mattieu | Chief Medical Officer | Oct 12 | Sale for tax withholding · S | −422 | $8.63 | −$3.64K | 19,857 |
| Shook David | Chief Medical Officer | Sep 10 | Sale for tax withholding · S | −500 | $12.70 | −$6.35K | 20,423 |
| Hill Stephen J. | Chief Operating Officer | Aug 21 | Sale for tax withholding · S | −989 | $15.54 | −$15.4K | 16,816 |
| Seely Lynn | President and CEO | Aug 21 | Sale for tax withholding · S | −9,589 | $15.54 | −$149K | 63,899 |
| Lee Gary K. | Chief Scientific Officer | Aug 21 | Sale for tax withholding · S | −1,457 | $15.54 | −$22.6K | 16,220 |
| Seely Lynn | President and CEO | Aug 10 | Sale for tax withholding · S | −390 | $14.34 | −$5.59K | 73,488 |
| Hill Stephen J. | Chief Operating Officer | Aug 10 | Sale for tax withholding · S | −89 | $14.34 | −$1.28K | 17,805 |
| Lee Gary K. | Chief Scientific Officer | Aug 10 | Sale for tax withholding · S | −131 | $14.34 | −$1.88K | 17,677 |
| Bulis Veronica Sanchez | VP, Corporate Controller | Aug 10 | Sale for tax withholding · S | −621 | $14.34 | −$8.91K | 14,799 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 27 | Other Transaction · J | −38,500 | — | — | 2,818,980 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 27 | Other Transaction · J | −44,000 | — | — | 2,774,980 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 17 | Open-market sale · S | −10 | $13.70 | −$137 | 2,857,480 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jul 16 | Open-market sale · S | −10 | $13.73 | −$137 | 2,857,490 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jun 29 | Other Transaction · J | −76,000 | — | — | 2,857,500 |
| Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Jun 15 | Other Transaction · J | −66,500 | — | — | 2,933,500 |
| Shook David | Chief Medical Officer | Jun 10 | Sale for tax withholding · S | −1,977 | $12.64 | −$25K | 20,923 |
| Bulis Veronica Sanchez | VP, Corporate Controller | May 11 | Sale for tax withholding · S | −217 | $18.91 | −$4.1K | 15,420 |
| Seely Lynn | President and CEO | May 11 | Sale for tax withholding · S | −388 | $18.91 | −$7.34K | 73,878 |
| Lee Gary K. | Chief Scientific Officer | May 11 | Sale for tax withholding · S | −130 | $18.92 | −$2.46K | 17,808 |
| Hill Stephen J. | Chief Operating Officer | May 11 | Sale for tax withholding · S | −89 | $18.92 | −$1.68K | 17,894 |
Loading...
